Bristol Myers Squibb operations and portfolio, background for the shares

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-30, 07:37.

Bristol Myers Squibb (US0897961004) is a major U.S. biopharmaceutical company listed on the New York Stock Exchange, and its shares are closely watched by global healthcare investors who track large-cap drug makers in oncology and cardiology. The company sits among the leading names in immuno-oncology and cardiovascular treatment, and its long-term prospects depend on how it manages patent expirations and brings new medicines to market.

How Bristol Myers Squibb operates today

Bristol Myers Squibb is headquartered in the United States and focuses on the discovery, development, and commercialization of prescription medicines in areas such as oncology, hematology, immunology, and cardiovascular disease. Its research and development efforts span early-stage discovery laboratories and late-stage clinical trials, reflecting the high-cost and high-risk nature of pharmaceutical innovation.

The company typically advances drug candidates through multiple phases of clinical trials before seeking regulatory approval from authorities like the U.S. Food and Drug Administration and the European Medicines Agency. These approvals determine when a new product can be launched, how it is labeled, and which patient populations it can serve, which makes regulatory outcomes central to the future revenue profile.

Key revenue pillars and patent cycles

Bristol Myers Squibb derives a large share of its revenue from a handful of established, high-selling drugs, many of which were acquired or co-developed with partners and now face evolving competitive and patent dynamics. The company has historically depended on blockbuster medicines to fund its research pipeline and shareholder returns, so the timing of patent expirations and generic or biosimilar entry is a critical factor in how investors evaluate the stock.

To address upcoming patent cliffs, Bristol Myers Squibb invests heavily in next-generation therapies and life-cycle management strategies, such as developing new indications for existing drugs, new formulations, or combination regimens. This approach aims to extend the commercial life of key molecules while diversifying the portfolio into new disease areas with unmet medical needs and less crowded competitive landscapes.

What the company sells

Bristol Myers Squibb markets a portfolio of prescription drugs, including the immuno-oncology therapy Opdivo for various cancers and the oral anticoagulant Eliquis for stroke prevention in atrial fibrillation, among other indications. These medicines are prescribed by physicians and dispensed through pharmacies and hospital channels, forming core revenue streams in oncology and cardiovascular care.

Where the stock trades today

Bristol Myers Squibb stock trades on the New York Stock Exchange in U.S. dollars, and the latest verifiable price information should be taken from a current market quote on the trading day in question.

This article was produced with AI assistance and editorially reviewed. Price and company figures without guarantee; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions carry risks up to and including total loss.